Consistently, TP53 mutation-bearing tumors tend to be more resistant to various cancer chemotherapies [4, 9–11] and radiotherapy [10–12], and more aggressive TP53 R273 and R248 mutants are associated with accelerated cancer progression in colorectal tumors [13]. This evidence concerns the gene TP53 and colorectal neoplasm.